Investigating how CCL2 and CCR2 signaling affects various diseases and discovering new natural products.
Official title: Signaling mediators of CCL2/CCR2 and natural product discovery
Funded at Charles R. Drew University of Med & Sci · NIH-11075340 · Data updated 2026-11-12
This study is looking at how a specific protein and its receptor affect diseases like obesity, diabetes, and cancer, with the hope of finding new ways to treat these conditions that could help patients feel better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Charles R. Drew University of Med & Sci NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | May 1, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $361,250 |
| NIH project number | 5R35GM149318-03 |
| Project ID | NIH-11075340 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals suffering from obesity, diabetes, or cardiovascular diseases who are interested in novel treatment approaches.
✕Less likely to help
Patients with conditions unrelated to the CCL2-CCR2 signaling pathway may not benefit from this research.
What this research studies
This research focuses on understanding the role of CCL2 and its receptor CCR2 in various diseases, including obesity, diabetes, and cancer. By exploring how these signaling pathways work, the researchers aim to identify new therapeutic targets and natural products that could help manage these conditions. The study will involve detailed analysis of the intracellular mechanisms involved in CCL2-CCR2 signaling and how other chemokines may compensate when this pathway is blocked. Patients may benefit from insights that could lead to new treatments for their conditions.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve treatment options for patients with obesity, diabetes, and cardiovascular diseases.
How similar studies have gone: Previous research has shown promise in targeting chemokine signaling pathways, but this specific approach is still being explored.
Where this research is happening
-
Charles R. Drew University of Med & Sci
Los Angeles, United States Active
Researchers
- Principal investigator: Wang, Piwen — Charles R. Drew University of Med & Sci
- Study coordinator: Wang, Piwen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.